Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms
Nutrients · 17.02.2024 · 16 (4) · 559
DOI: 10.3390/nu16040559 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 17.02.2024. Verfasst von Marta Włodarczyk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland. Hauptthemen laut MEDLINE: Endometriosis, Polycystic Ovary Syndrome, Catechin, Leiomyoma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 272 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS.
Abstract (Originalsprache)
The most common malignant gynecologic diseases are cervical, uterine, ovarian, vaginal, and vulvar cancer. Among them, ovarian cancer causes more deaths than any other cancer of the female reproductive system. A great number of women suffer from endometriosis, uterine fibroids (UFs), adenomyosis, dysmenorrhea, and polycystic ovary syndrome (PCOS), which are widespread benign health problems causing troublesome and painful symptoms and significantly impairing the quality of life of affected women, and they are some of the main causes of infertility. In addition to the available surgical and pharmacological options, the effects of supporting standard treatment with naturally occurring compounds, mainly polyphenols, are being studied. Catechins are responsible for the majority of potential health benefits attributed to green tea consumption. Epigallocatechin gallate (EGCG) is considered a non-toxic, natural compound with potential anticancer properties. Antioxidant action is its most common function, but attention is also drawn to its participation in cell division inhibition, apoptosis stimulation and epigenetic regulation. In this narrative review, we describe the role of EGCG consumption in preventing the development of benign reproductive disorders such as UF, endometriosis, and PCOS, as well as malignant gynecologic conditions. We discuss possible epigenetic mechanisms that may be related to the action of EGCG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland.
- Centre for Preclinical Research, Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland.
- Second Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, 00-189 Warsaw, Poland.
- Warsaw Institute of Women's Health, 00-189 Warsaw, Poland.
- Development and Research Center of Non-Invasive Therapies, Pro-Familia Hospital, 35-302 Rzeszów, Poland.
- Department of Obstetrics and Gynecology, Pro-Familia Hospital, 35-302 Rzeszow, Poland.
ORCID-Profile: Marta Włodarczyk, Michał Ciebiera, Grażyna Nowicka, Mohamed Ali, Ayman Al-Hendy
Förderung
- NIEHS NIH HHS
Zitieren
APA
Włodarczyk, M., Ciebiera, M., Nowicka, G., Łoziński, T., Ali, M., & Al-Hendy, A. (2024). Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms. Nutrients, 16(4), 559. https://doi.org/10.3390/nu16040559
Vancouver
Włodarczyk M, Ciebiera M, Nowicka G, Łoziński T, Ali M, Al-Hendy A. Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms. Nutrients. 2024;16(4):559. doi:10.3390/nu16040559
BibTeX
@article{Wodarczyk2024,
author = {Włodarczyk, Marta and Ciebiera, Michał and Nowicka, Grażyna and Łoziński, Tomasz and Ali, Mohamed and Al-Hendy, Ayman},
title = {Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {4},
pages = {559},
doi = {10.3390/nu16040559}
}
EUVIMED